Catalog Number Pack Size List Price* Promo Price* Quantity
HY-10182-5MG 5 mg 88,00 66,00 Add
HY-10182-1ML 10 mM * 1 mL 96,00 72,00 Add
HY-10182-10MG 10 mg 135,00 101,30 Add
HY-10182-50MG 50 mg 392,00 294,00 Add
HY-10182-100MG 100 mg 621,00 465,80 Add
HY-10182-S-1ST Sample   Inquire

* CHF, excl. 7.7% VAT and shipping costs

Product Description

Best price guarantee – we offer you the lowest price in Switzerland. Please contact us for a quote if needed.

CHIR-99021; CT99021
Laduviglusib (CHIR-99021) is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy.

Category Biochemicals
Supplier MedChem Express
Regulatory Status RUO
Research Field Cancer, PI3K/Akt/mTOR, Stem Cell/Wnt, Autophagy
Format Solubility: DMSO : 16.67 mg/mL (35.82 mM; Need ultrasonic)
Grade Clinical information: No Development Reported
Purity 98%
Molecular Formula C22H18Cl2N8
Molecular Weight 465.34
CAS-Number 252917-06-9
Storage Conditions Powder -20°C 3 years, 4°C 2 years; In solvent -80°C 6 months, -20°C 1 month
References CT99021
Tech. Data Sheet View datasheet
Link To Supplier
Shipping Details Room temperature
Material Safety Data Sheet Download PDF